tigemonam

structure given in first source

Also Known As:

SQ 30836; SQ-30836; Acetic acid, (((1-(2-amino-4-thiazolyl)-2-((2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-, (S-(Z))-

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Infections 09/01/1988 - "It is concluded that tigemonam is a candidate for clinical trials in patients with infections caused by Gram-negative aerobes other than pseudomonas and acinetobacter." 02/01/1987 - "In localized infections, tigemonam also demonstrated excellent in vivo activity. " 02/01/1987 - "In a variety of gram-negative systemic infections in mice, orally administered tigemonam was efficacious in all infections studied. " 02/01/1989 - "Tigemonam may have a valuable role in the management of infection caused by enterobacteria, particularly if bioavailability following oral administration is confirmed in human subjects."
2.	Community-Acquired Infections 05/01/1989 - "It is concluded that tigemonam should play an important role in the treatment of nosocomial infections that do not require parenteral therapy and in the treatment of multiresistant community-acquired infections." 05/01/1989 - "It is concluded that tigemonam should play an important role in the treatment of nosocomial infections that do not require parenteral therapy and in the treatment of multiresistant community-acquired infections."
3.	Cross Infection (Nosocomial Infection) 05/01/1989 - "It is concluded that tigemonam should play an important role in the treatment of nosocomial infections that do not require parenteral therapy and in the treatment of multiresistant community-acquired infections." 05/01/1989 - "It is concluded that tigemonam should play an important role in the treatment of nosocomial infections that do not require parenteral therapy and in the treatment of multiresistant community-acquired infections."
4.	Pyelonephritis 02/01/1987 - "In acute pyelonephritis in mice caused by Escherichia coli or Proteus sp., tigemonam was very effective. "

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration